Purpose Crizotinib, a mesenchymal-epithelial transition/anaplastic lymphoma kinase/c-ros
oncogene 1 (ROS1) inhibitor, has recently been approved by the US Food and Drug …

Background The receptor tyrosine kinase ROS1 is a driver gene in the non-small cell lung
cancer (NSCLC) with promising target treatment potential. The clinical features of NSCLC …

Background To determine the prevalence and clinicopathological features of ROS1 fusions
in Chinese patients with non-small-cell lung cancer (NSCLC). Methods Formalin-fixed and …

Patients with non-small cell lung cancer (NSCLC) harboring ROS proto-oncogene 1 (ROS1)
gene rearrangements show dramatic response to the tyrosine kinase inhibitor (TKI) …

Background ROS1 gene rearrangement has been reported in several types of cancers,
including non-small cell lung cancer (NSCLC). It is reported that tyrosine kinase inhibitors …

Purpose: Oncogenic gene fusions involving the 3′ region of ROS1 kinase have been
identified in various human cancers. In this study, we sought to characterize ROS1 fusion …

Background The study was conducted to investigate the clinicopathological features and
prevalence of ROS1 gene fusion in Chinese patients with non‐small cell lung cancer …

ROS1 rearranged non-small-cell lung cancer (NSCLC) is a distinct molecular subtype of
NSCLC, accounting for 2% of cases. Typically, these are genomic rearrangements resulting …

The ROS1 kinase is an oncogenic driver in non-small-cell lung cancer (NSCLC). Fusion
events involving the ROS1 gene are found in 1%–2% of NSCLC patients and lead to …

Background ROS1 gene fusion represents a specific subtype of non‐small cell lung cancer
(NSCLC). Crizotinib is recommended for ROS1‐positive NSCLC due to its favorable …